Embecta CORP

Embecta Corp. has filed an amendment to its Form 8-K to include the audited financial statements of Owen Mumford Holdings Limited and pro forma financial information following its acquisition.

Embecta Corp. has finalized its acquisition of UK-based medical device innovator Owen Mumford Holdings Limited for an upfront cash payment and potential milestone-based payments.

Embecta Corp. reported a significant decline in second-quarter fiscal 2026 revenue and lowered its full-year financial guidance, citing challenges in its U.S. business and the impending acquisition of Owen Mumford.

Embecta Corp. announced the results of its 2026 Annual Meeting of Stockholders, with all director nominees elected and key proposals approved.

Embecta Corp. reported largely expected first-quarter fiscal 2026 financial results, with revenues of $261.2 million and a focus on strategic transformation and debt reduction.

Embecta Corp. reported mixed fiscal year 2025 results with revenue declines but improved profitability, exceeding adjusted operating and EBITDA margin targets, while providing initial fiscal year 2026 guidance.

Embecta Corp. reported a revenue decrease for the second quarter of fiscal year 2026, alongside progress on its acquisition of Owen Mumford Holdings Limited.

Embecta Corp. reported a significant turnaround in net income for the first fiscal quarter of 2026, driven by substantial cost reductions and a strategic asset sale, despite flat revenues.

Embecta Corp. reports a significant increase in net income and operating profit for the third quarter, driven by cost reductions and strategic refocusing on its core diabetes care business.

Embecta Corp.'s Q2 2025 results reveal a revenue decrease, driven by volume declines and unfavorable foreign currency impacts, while the company continues to execute its restructuring plans.

Embecta Corp. reports a decrease in revenue and net income for the first quarter of fiscal year 2025, alongside the discontinuation of its patch pump program.

Embecta Corp. experienced a slight revenue decrease and a significant drop in operating income in the third quarter of 2024, while navigating ongoing business transitions and market pressures.

Embecta Corp. reports a strategic pivot away from its patch pump program, leading to increased net income despite a slight revenue decline in its 2025 fiscal year.

Embecta Corp.'s 2024 annual report highlights a strategic shift away from patch pump development, alongside a review of its financial performance and operational challenges.

Embecta Corp. has filed an amendment to its annual report to correct a minor error in the certifications related to internal control over financial reporting.

Embecta Corp. reports that VP, Chief Accounting Officer Anthony M. Roth acquired 30,000 shares of common stock on June 1, 2026.

Embecta Corp. Director Carrie L Anderson acquired 22,841 shares of common stock through a grant, increasing her total beneficial ownership.

Embecta Corp. Director Robert J. Hombach increased his beneficial ownership by 22,841 shares of common stock through a grant.

Embecta Corp. Director Milton Mayo Morris acquired 22,841 shares of common stock, increasing his total beneficial ownership to over 60,000 shares.

Embecta Corp. Director Karen Prange acquired 22,841 shares of common stock, increasing her total beneficial ownership to over 64,000 shares.

Embecta Corp. Director Claire Pomeroy acquired 22,841 shares of common stock, increasing her beneficial ownership to 66,127.164 shares.

Embecta Corp. issued a supplement to its proxy statement, addressing Institutional Shareholder Services' negative recommendation on a proposal to increase shares for its 2022 equity compensation plan.

Embecta Corp. has filed definitive additional materials for its proxy statement with the SEC.

Embecta Corp. reports strong fiscal year 2025 execution, exceeding adjusted operating margin targets, reducing debt, and advancing GLP-1 growth initiatives, while outlining strategic priorities for 2026.

Embecta Corp. has filed a definitive proxy statement with the Securities and Exchange Commission.

Embecta Corp. has announced its 2025 Annual Meeting of Stockholders and detailed its progress as an independent company, including strengthening its core business and investing for growth.

BlackRock, Inc. has reported a beneficial ownership of 7.7% in Embecta Corp's common stock as of June 30, 2026.

River Road Asset Management, LLC has filed an amendment to its Schedule 13G, reporting zero beneficial ownership of Embecta Corp. common stock as of May 26, 2026.

Yacktman Asset Management LP and AMG Yacktman Fund report a combined beneficial ownership of 6.2% of Embecta Corp. common stock as of March 31, 2026.

American Century Investment Management and affiliated entities have reported a 5.8% beneficial ownership stake in Embecta Corp. common stock.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.07% beneficial ownership stake in Embecta Corp.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Embecta Corp common stock following an internal realignment effective January 12, 2026.